Artivion, Inc.（AORT）財務資料AORTArtivion, Inc.

Artivion, Inc. (AORT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Aortic stent grafts, accounting for 38.2% of total sales, equivalent to $44.40M. Other significant revenue streams include On X and Preservation Services. Understanding this composition is critical for investors evaluating how AORT navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Artivion, Inc. maintains a gross margin of 64.03%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -0.29%, while the net margin is -10.74%. These profitability ratios, combined with a Return on Equity (ROE) of -0.73%, provide a clear picture of how effectively AORT converts its operational activities into shareholder value.

In the context of the broader market, AORT competes directly with industry leaders such as STAA and PRCT. With a market capitalization of $1.07B, it holds a significant position in the sector. When comparing efficiency, AORT's gross margin of 64.03% stands against STAA's 74.55% and PRCT's 66.01%. Such benchmarking helps identify whether Artivion, Inc. is trading at a premium or discount relative to its financial performance.

Artivion has shown a gross margin of 64.03% in Q2 2026, indicating solid profitability potential despite recent net income challenges. The company has also seen total revenue growth, with Q2 2026 revenue at $125.76 million, up from $112.97 million in Q2 2025.